Surcinelli, Andrea; Kalincik, Tomas; Roos, Izanne; D'amico, Emanuele; Lechner-Scott, Jeannette; Ozakbas, Serkan; Hradilek, Pavel; Horakova, Dana; Vachova, Marta; Panzera, Ivan; Ruzza, Stefano; Piscaglia, María-Grazia; Gerlach, Oliver; Meca-Lallana, José-Eustasio; Valero-López, Gabriel; Kermode, Allan-G; Fabis-Pedrini, Marzena-J; Prevost, Julie; Ampapa, Radek; Hodgkinson, Suzanne; Grand'maison, Francois; Khoury, Samia-J; John, Nevin-A; Peterka, Marek; Houskova, Jana; Recmanova, Eva; Rous, Zuzana; Shaygannejad, Vahid; Alroughani, Raed; Kuhle, Jens; Jakob, Gregor-Brecl; Grammond, Pierre; Patti, Francesco; Van-Der-Walt, Anneke; Butzkueven, Helmut; Foschi, Matteo
(SAGE PUBLICATIONS LTD, 2026-03)
BACKGROUND: Late-onset multiple sclerosis (LOMS), defined by symptom onset after age 50, is increasingly recognised as a distinct clinical entity. Evidence comparing disease-modifying therapies (DMTs) in this subgroup ...